Our recent report indicating that genetic and pharmacological inhibition of TG2 restricts Mtb replication in macrophages (16) prompted us to investigate the potential usefulness of the TG2 inhibitors cystamine and cysteamine as HDTs against TB. The gene discussed is TGM2; the disease is tuberculosis.